Figures
- Figure 1–
Key research steps in pulmonary fibrosis.
- Figure 2–
Schematic pathogenic steps in pulmonary fibrosis (as discussed during the 2012 ICLAF). Th: T-helper cell; CTGF: connective tissue growth factor; TGF: transforming growth factor; PDGF: platelet-derived growth factor; ROCK: Rho-associated protein kinase; NOX: NADPH oxidase; LOXL: lysyl oxidase; S1P–S1P1: sphingosine-1-phosphate–sphingosine-1-phosphate receptor 1; mTOR: mammalian target of rapamycin; EMT: epithelial–mesenchymal transition.
- Figure 3–
Collective efforts lead to improved outcomes for patients with pulmonary fibrosis. FDA: Food and Drug Administration; EMA: European Medicines Agency.
Additional Files
Files in this Data Supplement:
Vol 42 Issue 1
Table of Contents
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis
